2017 American Transplant Congress
Inhibition of Memory T Cell Alloresponses by TIM-1+ B Cells.
Background:Alloreactive memory T cells mediate accelerated rejection of allografts and prevent tolerance induction. While regulatory B cells (Bregs) can promote tolerance induction through suppression of…2017 American Transplant Congress
Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.
1U of Cincinnati, Cincinnati, OH; 2Cincinnati Children's, Cincinnati, OH
Purpose: Bone marrow niche-resident plasma cells (BMNRPCs) exhibit variable sensitivity to proteasome inhibitor (PI) therapy. Here, we characterized alterations in the gene and protein expression…2017 American Transplant Congress
Inflammatory Conditions Dictate the Effect of MSC on B Cell Function.
The immunomodulatory capacity of mesenchymal stem or stromal cells (MSC) makes them a promising therapeutic tool for immune disease and organ transplantation. The effects of…2017 American Transplant Congress
Hypogammaglobulinemia in Pediatric Heart Transplant Candidates Is Not Corrected by Transplantation.
Introduction: Hypogammaglobulinemia (HG) is associated with poor outcomes in adult heart transplant recipients but is not well studied in pediatric recipients. We therefore investigated longitudinal…2017 American Transplant Congress
Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction.
Background: Development of chronic lung allograft dysfunction (CLAD) limits long-term success from lung transplantation (LTx). Elicitation of de novo antibody (Ab) to mismatched donor HLA…2017 American Transplant Congress
Percentage of CD19+ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.
Urology, Hokkaido University, Sapporo, Japan
[Introduction] Administration of rituximab to ABO-incompatible kidney transplant (ABOi-KTx) recipients is recognized as effective and safe. A single dose of 375 mg/m2 rituximab is generally…2017 American Transplant Congress
A Novel Role for MyD88 Signaling Downstream from Toll-Like Receptors in B Cells Responding to Blood Group Antigens.
Hiroshima University, Hiroshima, Japan
[Introduction]Although there is some empirical evidence that severe infectious complications provoke refractory AMR following ABO-incompatible transplantations (ABOi-Tx), its mechanism remains unclear. Here, we investigated a…2017 American Transplant Congress
TFR:TFH Cell Ratio Correlates with Anti-Donor Germinal Center Reactivity and Donor-Specific Antibody Formation Following Transplantation.
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
Kidney transplantation is the treatment of choice for patients with end-stage renal disease. Although short-term outcomes are excellent, long-term allograft survival rates remain inadequate. It…2017 American Transplant Congress
Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.
Background. Plasmapheresis for antibody removal and rituximab for antibody production suppression are performed for desensitization against ABO-incompatible kidney transplantation. We evaluated clinical outcome for optimizing…2017 American Transplant Congress
Expansion, Function and Clonotypic Analysis of Human Alloreactive Treg Stimulated with Different Dendritic Cell Populations or CD40L-Stimulated B Cells.
Purpose:In order to establish a protocol to generate large numbers of human alloantigen-reactive regulatory T cells (arTreg) with potent allospecific suppressive capacity for therapeutic application,…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 35
- Next Page »